Results 11 to 20 of about 6,111 (249)

Tofacitinib: A Promising Therapeutic Option for Refractory Pityriasis Rubra Pilaris—A Case Report [PDF]

Clinical Case Reports
Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disorder that can severely impact the quality of life in patients, particularly when presenting in chronic or refractory form. Emerging evidence suggests that JAK inhibitors may offer a potential
Mahsa Taremi, Nikoo Mozafari
doaj   +3 more sources

A case of pityriasis rubra pilaris secondary to ponatinib [PDF]

SAGE Open Medical Case Reports
Ponatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia and acute lymphoblastic leukemia, can cause rare cutaneous side effects. In this case, a 63-year-old woman developed a pityriasis rubra pilaris-like eruption 1 month after starting ...
Ariana Nateghi, Florence Lagacé-Thomassin, Julie Desrochers   +2 more
doaj   +3 more sources

Targeting IL-1 controls refractory pityriasis rubra pilaris. [PDF]

Sci Adv
Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease with a poorly understood pathogenesis. Through a molecularly driven precision medicine approach and an extensive mechanistic pathway analysis in PRP skin samples, compared to psoriasis ...
Schmauch E, Severin Y, Xing X, Mangold A, Conrad C, Johansen P, Kahlenberg JM, Mellett M, Navarini A, Nobbe S, Sarkar MK, Satyam A, Tsoi LC, French LE, Nilsson J, Linna-Kuosmanen S, Kaikkonen MU, Snijder B, Kellis M, Gudjonsson JE, Tsokos GC, Contassot E, Kolios AGA.   +22 more
europepmc   +4 more sources

Misdiagnosed Pityriasis Rubra Pilaris Successfully Managed With Isotretinoin: A Case Series. [PDF]

Cureus, 2023
Being a rare inflammatory, hyperproliferative dermatosis, diagnosing pityriasis rubra pilaris (PRP) can be a challenge to many clinicians. Our case reports aim to demonstrate that PRP is frequently diagnosed and managed as atopic dermatitis (AD) and that
Al Khalifa N, Alsabbagh M, Raees M, Aljufairi E.   +3 more
europepmc   +4 more sources

Refractory pityriasis rubra pilaris treated with upadacitinib [PDF]

JAAD Case Reports, 2023
Eingun James Song, MD, Miriam A. Al-Saedy, BS, Nicole Bouché, BS   +2 more
doaj   +3 more sources

Grover's disease-like patterns in early pityriasis rubra pilaris. [PDF]

J Dtsch Dermatol Ges
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 23, Issue 2, Page 231-233, February 2025.
Hoffmann J, Durani B, Hartschuh W.
europepmc   +3 more sources

The comprehensive impact of pityriasis rubra pilaris on physical symptoms, mental health, and activities of daily living: A mixed methods study

JEADV Clinical Practice, 2023
Background Pityriasis rubra pilaris (PRP) is a rare and often severe inflammatory skin disorder with major detriment to patients' quality of life. While past studies have described in detail the morphologic and histopathologic presentations of PRP ...
Rose C. Velasco, Brett Cutler, William McCue, Teri M. Greiling   +3 more
doaj   +2 more sources

A Review of Pityriasis Rubra Pilaris and Rheumatologic Associations [PDF]

Clinical and Developmental Immunology, 2004
Pityriasis rubra pilaris (PRP) is a rare group of hyperkeratotic, papulosquamous disease that can be acquired or inherited. There have been reported cases of rheumatologic associations, mainly arthritis and ...
Happy Chan, Fu Tong Liu, Stanley Naguwa   +2 more
doaj   +5 more sources

Pityriasis Rubra Pilaris

Journal of the American Academy of Dermatology
Greiling TM, Brown F, Syed HA.
europepmc   +5 more sources

Pityriasis Rubra Pilaris

American Journal of Clinical Dermatology, 2012
Pityriasis rubra pilaris is an inflammatory papulosquamous skin disease of unknown etiology. Incidence rates vary between 1:5,000-1:50,000. Six subtypes are differentiated on clinical background. The juvenile circumscribed subtype has best prognosis. Generalized disease impairs quality of life of patients.
Leger, Marie, Newlove, Tracey, Robinson, Maria, Patel, Risha, Meehan, Shane, Ramachandran, Sarika   +5 more
exaly   +6 more sources